A Phase 3 clinical trial investigating semaglutide in combination with insulin icodec for patients with Type 2 Diabetes completed its primary phase on 2025-04-14. The study, which enrolled 148 participants, aimed to evaluate the efficacy of this weekly insulin regimen in reducing blood sugar levels.
Background
This study explores the combined use of semaglutide, a well-established treatment for Type 2 Diabetes, with insulin icodec, a new weekly insulin. The trial's objective was to assess how this combination helps in reducing blood sugar levels in patients with Type 2 Diabetes.
Trial design
The study, identified as NCT05813912, is a Phase 3 clinical trial that enrolled 148 participants. It investigates the treatment of Diabetes Mellitus, Type 2. The trial's design involved participants receiving insulin icodec once a week during an initial 26-week run-in period. Participants whose blood sugar levels did not normalize after this period proceeded to a second 26-week intensification period, where they received both insulin icodec and semaglutide. If blood sugar levels normalized during the run-in period, participants entered a 5-week follow-up period.
What this means
The primary completion of this Phase 3 trial marks the conclusion of the data collection phase for evaluating the combined use of semaglutide and insulin icodec in managing Type 2 Diabetes. While specific outcome measurements are not yet publicly available, the study's completion indicates that researchers have gathered the necessary data to assess the efficacy and safety profile of this novel weekly insulin regimen alongside semaglutide for blood sugar reduction. Future data releases are anticipated to provide detailed insights into these findings.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05813912, titled "A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes," was posted on 2025-04-14 on clinicaltrials.gov.